Chen Leichong, Zhang Sijia, Li Qianwen, Li Junyu, Deng Huilin, Zhang Sheng, Meng Rui
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China.
Front Oncol. 2022 Dec 1;12:1065027. doi: 10.3389/fonc.2022.1065027. eCollection 2022.
Protein kinase CK2, a conserved serine/threonine-protein kinase, is ubiquitous in cells and regulates various intracellular processes, especially in tumor cells. As one of the earliest discovered protein kinases in humans, CK2 plays a crucial role in phosphorylating or associating with hundreds of substrates to modulate several signaling pathways. Excellent reviews have reported that the overexpression of CK2 could be observed in many cancers and was closely associated with tumor occurrence and development. The elevation of CK2 is also an indicator of a poor prognosis. Recently, increasing attention has been paid to the relationship between CK2 and tumor immunity. However, there is no comprehensive description of how CK2 regulates the immune cells in the tumor microenvironment (TME). Also, the underlying mechanisms are still not very clear. In this review, we systematically summarized the correlation between CK2 and tumor immunity, primarily the effects on various immune cells, both in innate and adaptive immunity in the TME. With the comprehensive development of immunotherapy and the mounting transformation research of CK2 inhibitors from the bench to the clinic, this review will provide vital information to find new treatment options for enhancing the efficacy of immunotherapy.
蛋白激酶CK2是一种保守的丝氨酸/苏氨酸蛋白激酶,在细胞中广泛存在,并调节各种细胞内过程,尤其是在肿瘤细胞中。作为人类最早发现的蛋白激酶之一,CK2在磷酸化数百种底物或与它们结合以调节多种信号通路方面发挥着关键作用。优秀的综述报道,在许多癌症中都能观察到CK2的过表达,并且它与肿瘤的发生和发展密切相关。CK2的升高也是预后不良的一个指标。最近,人们越来越关注CK2与肿瘤免疫之间的关系。然而,关于CK2如何调节肿瘤微环境(TME)中的免疫细胞,目前尚无全面的描述。而且,其潜在机制仍不是很清楚。在这篇综述中,我们系统地总结了CK2与肿瘤免疫之间的相关性,主要是其对TME中固有免疫和适应性免疫中各种免疫细胞的影响。随着免疫治疗的全面发展以及CK2抑制剂从实验室到临床的大量转化研究,这篇综述将为寻找提高免疫治疗疗效的新治疗选择提供重要信息。